Towards enhancing the predictive value of the microbiota for cancer immunotherapy

The gut microbiota has emerged as a potential determinant of immune checkpoint inhibitor (ICI) response, yet using it as a biomarker remains challenging. A recent study in Cell by Derosa et al. describes a two-tier model based on gut microbiota composition to discriminate responder from non-responde...

Full description

Saved in:
Bibliographic Details
Published inTrends in cancer Vol. 10; no. 9; p. 771
Main Authors Dzutsev, Amiran K, Goldszmid, Romina S
Format Journal Article
LanguageEnglish
Published United States 01.09.2024
Subjects
Biomarkers, Tumor - immunology
Gastrointestinal Microbiome - drug effects
Gastrointestinal Microbiome - immunology
Humans
Immune Checkpoint Inhibitors - pharmacology
Immune Checkpoint Inhibitors - therapeutic use
Immunotherapy - methods
Neoplasms - immunology
Neoplasms - microbiology
Neoplasms - therapy
Predictive Value of Tests
Online AccessGet more information

Cover

More Information
Summary:The gut microbiota has emerged as a potential determinant of immune checkpoint inhibitor (ICI) response, yet using it as a biomarker remains challenging. A recent study in Cell by Derosa et al. describes a two-tier model based on gut microbiota composition to discriminate responder from non-responder patients with cancer, offering new ideas that could be leveraged in the clinic.
ISSN:2405-8025
DOI:10.1016/j.trecan.2024.07.007